HK1137805A1 - 使用 的糖尿病診斷和風險分級 - Google Patents

使用 的糖尿病診斷和風險分級

Info

Publication number
HK1137805A1
HK1137805A1 HK10101315.4A HK10101315A HK1137805A1 HK 1137805 A1 HK1137805 A1 HK 1137805A1 HK 10101315 A HK10101315 A HK 10101315A HK 1137805 A1 HK1137805 A1 HK 1137805A1
Authority
HK
Hong Kong
Prior art keywords
proadm
diagnosis
risk assessment
pancreatic diabetes
pancreatic
Prior art date
Application number
HK10101315.4A
Other languages
English (en)
Inventor
‧博格曼
‧莫根塔勒
‧帕帕索提裡奧
‧斯塔克
Original Assignee
布拉姆斯有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 布拉姆斯有限公司 filed Critical 布拉姆斯有限公司
Publication of HK1137805A1 publication Critical patent/HK1137805A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK10101315.4A 2006-11-08 2010-02-05 使用 的糖尿病診斷和風險分級 HK1137805A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006052916A DE102006052916A1 (de) 2006-11-08 2006-11-08 Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM
PCT/DE2007/002018 WO2008055491A2 (de) 2006-11-08 2007-11-08 Diagnose und risikostratifizierung von diabetes mellitus mittels mr-proadm

Publications (1)

Publication Number Publication Date
HK1137805A1 true HK1137805A1 (zh) 2010-08-06

Family

ID=39277540

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10101315.4A HK1137805A1 (zh) 2006-11-08 2010-02-05 使用 的糖尿病診斷和風險分級
HK15103250.2A HK1203090A1 (zh) 2006-11-08 2010-02-05 使用 的糖尿病診斷和風險分級

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15103250.2A HK1203090A1 (zh) 2006-11-08 2010-02-05 使用 的糖尿病診斷和風險分級

Country Status (8)

Country Link
US (2) US20100035275A1 (zh)
EP (1) EP2097748B1 (zh)
JP (2) JP5275247B2 (zh)
CN (2) CN101568833B (zh)
DE (1) DE102006052916A1 (zh)
ES (1) ES2393262T3 (zh)
HK (2) HK1137805A1 (zh)
WO (1) WO2008055491A2 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
CA3086149A1 (en) 2006-04-04 2007-10-11 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
DE102007009751A1 (de) 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
JP5711131B2 (ja) * 2008-10-07 2015-04-30 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 最初の有害事象の予測のためのバイオマーカー
EP2180322A1 (en) * 2008-10-22 2010-04-28 BRAHMS Aktiengesellschaft Prognostic biomarkers for the progression of primary chronic kidney disease
WO2010049178A1 (en) * 2008-10-31 2010-05-06 B.R.A.H.M.S. Ag In vitro-method for the diagnosis, prognosis, monitoring and therapy follow-up of disorders associated with the metabolic syndrome, a cardiovascular disease and/or insulin resistance
WO2010049180A1 (en) * 2008-10-31 2010-05-06 B.R.A.H.M.S. Ag Methods and assays for classifying foodstuff and/or beverage and/or diet and/or nutrition regimen and/or medicament in view of an effect on the cardiovascular system
US20100159474A1 (en) * 2008-11-11 2010-06-24 B.R.A.H.M.S. Aktiengesellschaft Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
US8450069B2 (en) 2009-06-08 2013-05-28 Singulex, Inc. Highly sensitive biomarker panels
CN102472752B (zh) * 2009-08-28 2015-08-19 B.R.A.H.M.S有限公司 用于不良事件的预后的降钙素原
US20130302841A1 (en) * 2010-11-01 2013-11-14 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
EP2678360A1 (en) * 2011-02-21 2014-01-01 Fibrostatin, S.L. Methods for treating and diagnosing disease
EP2533052A1 (en) * 2011-06-07 2012-12-12 B.R.A.H.M.S GmbH Diagnostic use of proSomatostatin
CN104714020B (zh) * 2013-12-12 2016-05-25 张曼 尿液内源性α胰蛋白酶抑制剂重链H4在2型糖尿病合并冠心病中的应用
JP6944449B2 (ja) * 2015-11-27 2021-10-06 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 対象の細胞外液量状態のマーカーとしてのＭＲ−ｐｒｏＡＤＭ
WO2018029213A1 (en) * 2016-08-09 2018-02-15 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating organ dysfunction
RU2765212C2 (ru) * 2016-08-09 2022-01-26 Б.Р.А.Х.М.С. Гмбх Гистоны и/или proadm в качестве маркеров, свидетельствующих о неблагоприятном событии
EP3438668A1 (en) * 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnosis and risk stratification of fungal infections
EP3971572A1 (en) * 2017-09-13 2022-03-23 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
CN111630386A (zh) * 2017-11-17 2020-09-04 学校法人东海大学 糖尿病并发症用标志物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6320022B1 (en) * 1995-08-18 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Adrenomedullin peptides
DE19847690A1 (de) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
US6756783B2 (en) * 1999-06-01 2004-06-29 Merlin Technology, Inc Multi-frequency boring tool locating system and method
EP1214600B1 (en) * 1999-09-10 2005-12-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Determination of adrenomedullin-binding proteins
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
WO2004097423A1 (en) * 2003-04-25 2004-11-11 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
DE602004013135T2 (de) * 2004-07-22 2009-07-02 Brahms Aktiengesellschaft Verfahren für die Diagnose von schwerkranken Patienten
GB2418995B (en) * 2004-09-29 2006-08-16 Bookham Technology Plc Apodised binary grating
FI20050011A (fi) * 2005-01-05 2006-07-06 Jurilab Ltd Oy Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi

Also Published As

Publication number Publication date
JP5275247B2 (ja) 2013-08-28
JP2010509575A (ja) 2010-03-25
CN101568833B (zh) 2014-09-10
CN104198735B (zh) 2018-01-30
DE102006052916A1 (de) 2008-05-15
EP2097748B1 (de) 2012-08-08
US20160169912A1 (en) 2016-06-16
CN101568833A (zh) 2009-10-28
ES2393262T3 (es) 2012-12-19
CN104198735A (zh) 2014-12-10
HK1203090A1 (zh) 2015-10-16
WO2008055491A2 (de) 2008-05-15
WO2008055491A3 (de) 2008-08-21
EP2097748A2 (de) 2009-09-09
JP2013047689A (ja) 2013-03-07
US20100035275A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
HK1137805A1 (zh) 使用 的糖尿病診斷和風險分級
IL187859A0 (en) Diagnosis and prognosis of diabetes
EP2069768A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE-2 DIABETES
EP2350902A4 (en) METHODS OF RISK ASSESSMENT ASSOCIATED WITH MEDICAL DATA AND USES THEREOF
IL210856A0 (en) Combination therapy for the treatment of diabetes and related conditions
EP2056106A4 (en) SUGAR CHAIN INFLUENCE SUBSTANCE AND ITS USE
EP2001362A4 (en) QUANTITATIVE OPTOACUSTIC TOMOGRAPHY WITH REINFORCED CONTRASTS
EP2201370A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TYPE 2 DIABETES
EP2913327C0 (fr) Bleu de méthylène et son utilisation médicale
GB0616376D0 (en) Raman analysis of tissue
EP2094179A4 (en) EXTERNAL FASTENING ARRANGEMENT AND APPLICATION METHOD
EP2024745A4 (en) BIOLOGICAL ASSAYS FOR THE DIAGNOSIS AND EVALUATION OF FABRY DISEASE TREATMENT OPTIONS
EP1992287A4 (en) DISPLAY PROCEDURE FOR MEDICAL PICTURES AND PROGRAM THEREFOR
IL205353A0 (en) Diagnostic biomarkers of diabetes
IL192319A0 (en) Assessment of medical conditions
GB0608647D0 (en) Methods of diagnosis and treatment
EP2046129A4 (en) HERBICIDE COMPOSITION AND METHOD OF USE
GB0621822D0 (en) Predictor of nocturnal hypoglyceamia for individuals with diabetes
ZA200806808B (en) Treatment of stressed patients
GB201108964D0 (en) Medicament and method of diagnosis
EP2046128A4 (en) HERBICIDAL COMPOSITION AND METHOD FOR THEIR USE
EP2046116A4 (en) HERBICIDE COMPOSITION AND METHOD OF USE
GB0601950D0 (en) Compositions and methods of treating diabetes
EP2225559B8 (en) Assessment of physiological conditions
GB0709092D0 (en) Diagnosis and method of disease